HER2-TARGETED THERAPIES

Results from a multiregional population-based cohort analysis in Italy demonstrated that trastuzumab-associated cardiotoxicity may be limited to the treatment period, and that adding trastuzumab to adjuvant chemotherapy does not impact the long-term worsening of cardiovascular events